Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2022 Earnings Conference Call March 9, 2023 8:00 AM ET Company Participants Chris Calabrese - LifeSci Advisors, LLC Robert Gould - Interim Chief Executive Officer Esther Rajavelu - Chief Financial Officer Alan Ezekowitz - Board Member Conference Call Participants Matthew Harrison - Morgan Stanley Matthew Biegler - Oppenheimer Judah Frommer - Credit Suisse Dae Gon Ha - Stifel Edward Tenthoff - Piper Sandler Joseph Schwartz - SVB Securities Tazeen Ahmad - BofA S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38978 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its Charter) | Delaware | 47-4839948 | | --- | --- | | (St ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2022 Results Conference Call November 8, 2022 8:00 AM ET Company Participants Stephanie Ascher - Stern Investor Relations Bryan Stuart - President and Chief Executive Officer Esther Rajavelu - CFO Paul Bruno - Senior Vice President, Corporate Development Conference Call Participants Dae Gon Ha - Stifel Judah Frommer - Credit Suisse Matt Biegler - Oppenheimer Joseph Schwartz - SVB Leerink Operator Good morning, and welcome to Fulcrum Therapeutics Third Quarter 2022 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-4839948 (State or other j ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Stephanie Ascher - Stern, Investor Relations Bryan Stuart - President & Chief Executive Officer Judy Dunn - President, Research & Development Esther Rajavelu - Chief Financial Officer Paul Bruno - Executive Director, Corporate Development Conference Call Participants Judah Frommer - Credit Suisse Ted Tenthoff - Piper Sandler Dae Gon Ha - Stifel Matt Biegler - Oppenheimer Joseph Schwartz ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4839948 (State or other jurisd ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET Company Participants Naomi Aoki - SVP, Corporate Communications & IR Bryan Stuart - President & CEO Judy Dunn - President, R&D Esther Rajavelu - CFO Chris Morabito - CMO Paul Bruno - Executive Director, Corporate Development Conference Call Participants Judah Frommer - Credit Suisse Dae Gon Ha - Stifel Ted Tenthoff - Piper Sandler Joseph Schwartz - SVB Matt Biegler - Oppenheimer Operator Good morning and welcome ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38978 FULCRUM THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4839948 (State or other juris ...

Fulcrum Therapeutics March 2022 Disclaimer and Notice | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2021 Earnings Conference Call March 3, 2022 8:00 AM ET Company Participants Christi Waarich - Director of Investor Relations Bryan Stuart - President and Chief Executive Officer Judy Dunn - President of R&D Esther Rajavelu - Chief Financial Officer Chris Morabito - Chief Medical Officer Conference Call Participants Dae Gon Ha - Stifel Joseph Schwartz - SVB Securities Matthew Harrison - Morgan Stanley Judah Frommer - Credit Suisse Ted Tenthoff - Piper Sandler Discl ...